Better Biopharma – Details, episodes & analysis

Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria.

Check out Behnke's past appearance on Business Of Biotech: https: //www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and optimize manufacturing.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

In this episode of Better Biopharma, Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD. They discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and the development and manufacturing challenges behind the company's lead asset, APTN-101. 

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined which CDMO won Siren’s business.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson. The two talk about J&J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions